Recardio at BIO International Convention 2024
- haraldkattnig5
- Jun 3, 2024
- 1 min read
Updated: Mar 6, 2025
San Francisco, June 3, 2024 - Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced today that it is participating in the BIO International Convention 2024 in San Diego.
The conference is held annually and brings together the most innovative thinkers and leaders in biotechnology to provide opportunities through global partnerships, collaboration and thought leadership.
The conference is taking place on June 3-6, 2024 in San Diego.
Recardio is participating and presenting its latest advancements from its drug-based regenerative therapy and is giving a future outlook on new therapies and expansion programs.
About Recardio
Recardio Inc. is a late clinical-stage life science company focused on developing therapies for cardiovascular and other diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines critical for cardiac regeneration, resulting in healing cardiac tissue after an injury.
Recardio has received FDA and EMA clearance for a global pivotal phase III HEAL-MI clinical trial in acute myocardial infarction. This trial is planned to initiate in 2025 and will serve as the basis to apply for market authorization in major global markets. Recardio plans to fully develop its therapeutic platform for patients with various cardiovascular diseases. The company is headquartered in San Francisco, California, with operations in both the US and Europe.
For more information, visit: www.recardio.eu or contact pr@recardio.eu
